Phase 1 Evaluation of FluBHPVE6E7 Immunotherapy in HPV16-Associated Oropharyngeal Squamous Cell Carcinoma

The primary objective of this phase 1 study is to evaluate the safety and tolerability of **FluBHPVE6E7 immunotherapy** in patients with **HPV16-associated oropharyngeal squamous cell carcinoma**. This is clinically relevant as it addresses the need for effective treatments for cancers associated with **human papilloma virus (HPV)** infections, which are a significant cause of morbidity and mortality. The study aims to determine the potential of this immunotherapy to provide a new therapeutic option for affected patients. No secondary objectives are provided in the available data.

The clinical trial focuses on the **treatment of human papilloma virus (HPV) associated infections and cancers**. The study population includes both male and female participants, encompassing an age range that is categorized as adults. The trial involves a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants were selected based on criteria that include general health status and other relevant factors, though specific lifestyle considerations such as diet, physical activity, or habits have not been detailed. The trial aims to gather data from a diverse group, ensuring a comprehensive understanding of the treatment's effects across different demographics.

The clinical trial is designed to evaluate the efficacy and safety of **FluBHPVE6E7 immunotherapy** in patients with **HPV16-associated oropharyngeal squamous cell carcinoma**. This is a phase 3, randomized, double-blind, controlled study. The trial is expected to commence recruitment on April 29, 2024, and is estimated to conclude by July 1, 2029. Participants will be randomly assigned to receive either the investigational immunotherapy or a control treatment, with neither the participants nor the investigators aware of the group assignments to maintain blinding.

The study will include several key visits: an initial screening visit to determine eligibility, multiple follow-up visits to monitor treatment response and safety, and a final end-of-study visit. The screening visit will involve assessments to confirm the presence of **HPV16-associated oropharyngeal squamous cell carcinoma** and other inclusion criteria. Follow-up visits will occur at regular intervals to collect data on the primary and secondary endpoints, which include measures of efficacy and safety. The end-of-study visit will provide a comprehensive evaluation of the participant's health status and any long-term effects of the treatment.

Participant involvement is expected to last throughout the duration of the trial, with specific timelines for each phase of the study. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial's methodology ensures rigorous data collection and analysis to assess the potential benefits and risks of the investigational therapy in treating **HPV-associated infections and cancers**.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. The absence of these details precludes a comprehensive description of the treatment regimen, dosing schedules, or participant compliance monitoring. Consequently, the trial's treatment protocol remains unspecified based on the provided data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 29, 2024, with an estimated completion date of July 1, 2029. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.